Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Neuroinflammation
Published in: Journal of Neuroinflammation 1/2018

Open Access 01-12-2018 | Research

Vitamin D protects dopaminergic neurons against neuroinflammation and oxidative stress in hemiparkinsonian rats

Authors: Ludmila A R Lima, Maria Janice P Lopes, Roberta O Costa, Francisco Arnaldo V Lima, Kelly Rose T Neves, Iana B F Calou, Geanne M Andrade, Glauce S B Viana

Published in: Journal of Neuroinflammation | Issue 1/2018

Login to get access

Abstract

Background

The deficiency in 1α, 25-dihydroxyvitamin D3 (VD3) seems to increase the risk for neurodegenerative pathologies, including Parkinson’s disease (PD). The majority of its actions are mediated by the transcription factor, VD3 receptor (VD3R).

Methods

The neuroprotective effects of VD3 were investigated on a PD model. Male Wistar rats were divided into the following groups: sham-operated (SO), 6-OHDA-lesioned (non-treated), and 6-OHDA-lesioned and treated with VD3 (7 days before the lesion, pre-treatment or for 14 days after the 6-OHDA striatal lesion, post-treatment). Afterwards, the animals were subjected to behavioral tests and euthanized for striatal neurochemical and immunohistochemical assays. The data were analyzed by ANOVA and the Tukey test and considered significant for p < 0.05.

Results

We showed that pre- or post-treatments with VD3 reversed behavioral changes and improved the decreased DA contents of the 6-OHDA group. In addition, VD3 reduced the oxidative stress, increased (TH and DAT), and reduced (TNF-alpha) immunostainings in the lesioned striata. While significant decreases in VD3R immunoreactivity were observed after the 6-OHDA lesion, these changes were blocked after VD3 pre- or post-treatments. We showed that VD3 offers neuroprotection, decreasing behavioral changes, DA depletion, and oxidative stress. In addition, it reverses partially or completely TH, DAT, TNF-alpha, and VD3R decreases of immunoreactivities in the non-treated 6-OHDA group.

Conclusions

Taken together, VD3 effects could result from its anti-inflammatory and antioxidant actions and from its actions on VD3R. These findings should stimulate translational research towards the VD3 potential for prevention or treatment of neurodegenerative diseases, as PD.
Appendix
Available only for authorised users
Literature
1.
Olanow CW, et al. Levodopa in the treatment of Parkinson’s disease: current controversies. Mov Disord. 2004;19:997–1005.CrossRefPubMed
2.
Didonet JJ, et al. Neuropeptide S counteracts 6-OHDA-induced motor deficits in mice. Behav Brain Res. 2014;266:29–36.CrossRefPubMed
3.
4.
Hutson PH, Clark JA, Cross AJ. CNS target identification and validation: avoiding the valley of death or naive optimism? Annu Rev Pharmacol Toxicol. 2017;57:171–87.CrossRefPubMed
5.
Kubis AM, Piwowar A. The new insight on the regulatory role of the vitamin D3 in metabolic pathways characteristic for cancerogenesis and neurodegenerative diseases. Ageing Res Rev. 2015;24:126–37.CrossRefPubMed
6.
Berridge MJ. Vitamin D cell signalling in health and disease. Biochem Biophys Res Commun. 2015;460:53–71.CrossRefPubMed
7.
8.
Suzuki M, et al. 25-hydroxyvitamin D, vitamin D receptor gene polymorphisms, and severity of Parkinson’s disease. Mov Disord. 2012;27:264–71.CrossRefPubMed
9.
Peterson AL, Mancini M, Horak FB. The relationship between balance control and vitamin D in Parkinson's disease-a pilot study. Mov Disord. 2013;28:1133–7.CrossRefPubMed
10.
Suzuki M, et al. Randomized, double-blind, placebo-controlled trial of vitamin D supplementation in Parkinson disease. Am J Clin Nutr. 2013;97:1004–13.CrossRefPubMed
11.
Pike JW, Meyer MB. The vitamin receptor: new paradigm for the regulation of gene expression by 1,25-dihydroxyvitamin D3. Endocrinol Metab Clin N Am. 2010;39:255–69.CrossRef
12.
Christakos S, et al. Vitamin D: metabolism, molecular mechanism of action, and pleiotropic effects. Physiol Rev. 2016;96:365–408.CrossRefPubMed
13.
Groves NJ, McGrath JJ, Burne TH. Vitamin D as a neurosteroid affecting the developing and adult brain. Annu Rev Nutr. 2014;34:117–41.CrossRefPubMed
14.
Groves NJ, Burne TH. Sex-specific attenuated deficits in adult vitamin D deficient BALB/c mice. Physiol Behav. 2016;157:94–101.CrossRefPubMed
15.
16.
17.
Gascon-Barre M, Huet PM. Apparent [3H]1,25-dihydroxyvitamin D3 uptake by canine and rodent brain. Am J Phys. 1983;244(3):E266–71.
18.
Monnot C, et al. Asymmetric dopaminergic degeneration and levodopa alter functional corticostriatal connectivity bilaterally in experimental parkinsonism. Exp Neurol. 2017;292:11–20.CrossRefPubMedPubMedCentral
19.
Broadhurst PL. Determinants of emotionality in the rat. I. Situational factors. Br J Psychol. 1957;48:1–12.CrossRefPubMed
20.
Francardo V, et al. Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease. Neurobiol Dis. 2011;42:327–40.CrossRefPubMed
21.
Petit-Demouliere B, Chenu F, Bourin M. Forced swimming test in mice: a review of antidepressant activity. Psychopharmacology. 2004;177:245–55.CrossRefPubMed
22.
23.
Ahlskog JE. Challenging conventional wisdom: the etiologic role of dopamine oxidative stress in Parkinson’s disease. Mov Disord. 2005;20:271–82.CrossRefPubMed
24.
Green LC, et al. Analysis of nitrate, nitrite, and [15N] nitrate in biological fluids. Anal Biochem. 1982;126:131–8.CrossRefPubMed
25.
Draper HH, Hadley M. Malondialdehyde determination as index of lipid peroxidation. Methods Enzymol. 1990;186:421–31.CrossRefPubMed
26.
Ayala A, Muñoz MF, Argüelles S. Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. Oxid Med Cell Longevity. 2014;2014:31.CrossRef
27.
Zeiss CJ. Neuroanatomical phenotyping in the mouse: the dopaminergic system. Vet Pathol. 2005;42:753–73.CrossRefPubMed
28.
Björklund A, Dunnett SB. Dopamine neuron systems in the brain: an update. Trends Neurosci. 2007;30:194–202.CrossRefPubMed
29.
Gao R, et al. High frequency electro-acupuncture enhances striatum DAT and D1 receptor expression, but decreases D2 receptor level in 6-OHDA lesioned rats. Behav Brain Res. 2013;237:263–9.CrossRef
30.
31.
32.
Shen L, Ji HF. Associations between vitamin D status, supplementation, outdoor work and risk of Parkinson’s disease: a meta-analysis assessment. Nutrients. 2015;7:4817–27.CrossRefPubMedPubMedCentral
33.
34.
35.
36.
Larsson SC, et al. International Parkinson’s Disease Genomics Consortium (IPDGC). No clear support for a role for vitamin D in Parkinson’s disease: a Mendellian randomization study. Mov Disord. 2017;32:1249–52.CrossRefPubMedPubMedCentral
37.
Altemus KL, et al. Behavioral correlates of vitamin D deficiency. Physiol Behav. 1987;39:435–340.CrossRefPubMed
38.
39.
Anglin RES, et al. Vitamin D deficiency and depression in adults: systematic review and meta-analysis. Br J Psychiatry. 2013;202:100–7.CrossRefPubMed
40.
Gould JF, et al. Association of cord blood vitamin D at delivery with postpartum depression in Australian women. Aust NZ J Obstet Gynaecol. 2015;55(5):446–52.CrossRef
41.
Mozaffari-Khosravi H, et al. The effect of different single injections of high dose of vitamin D on improving the depression in depressed patients with vitamin D deficiency: a randomized clinical trial. J Clin Psychopharmacol. 2013;33(3):378–85.CrossRefPubMed
42.
Schaffer JA, et al. Vitamin D supplementation for depressive symptoms: a systematic review and meta-analysis of randomized controlled trials. Psychosom Med. 2014;76(3):190–6.CrossRef
43.
Pertile RA, Cui X, Eyles DW. Vitamin D signaling and the differentiation of developing dopamine systems. Neuroscience. 2016;333:193–203.CrossRefPubMed
44.
Kesby JP, Cui X, O'Loan J, JJ MG, Burne TH, Eyles DW. Developmental vitamin D deficiency alters dopamine-mediated behaviors and dopamine transporter function in adult female rats. Psychopharmacology. 2010;208(1):159–68.CrossRefPubMed
45.
Orme RP, et al. The role of vitamin D3 in the development and neuroprotection of midbrain dopamine neurons. Vitam Horm. 2016;100:273–97.CrossRefPubMed
46.
Eyles DW, et al. Distribution of the vitamin D receptor and 1α-hydroxylase in human brain. J Chem Neuroanat. 2005;29:21–30.CrossRefPubMed
47.
Cui X, et al. Vitamin D regulates tyrosine hydroxylase expression: N-cadherin a possible mediator. Neuroscience. 2015;304:90–100.CrossRefPubMed
48.
Sanchez B, et al. 1,25-Dihydroxyvitamin D3 administration to 6-hydroxydopamine-lesioned rats increases glial cell line-derived neurotrophic factor and partially restores tyrosine hydroxylase expression in substantia nigra and striatum. J Neurosci Res. 2009;87:723–32.CrossRefPubMed
49.
Kim JS, et al. 1a,25-Dihydroxyvitamin D3 protects dopaminergic neurons in rodent models of Parkinson’s disease through inhibition of microglial activation. J Clin Neurol. 2006;2:252–7.CrossRefPubMedPubMedCentral
50.
Smith MP, et al. Calcitriol protection against dopamine loss induced by intracerebroventricular administration of 6-hydroxydopamine. Neurochem Res. 2006;31:533–9.CrossRefPubMed
51.
Wang JY, et al. Vitamin D3 attenuates 6-hydroxydopamine-induced neurotoxicity in rats. Brain Res. 2001;904:67–75.CrossRefPubMed
52.
53.
Cass WA, et al. Calcitriol promotes augmented dopamine release in the lesioned striatum of 6-hydroxydopamine treated rats. Neurochem Res. 2014;39:1467–76.CrossRefPubMedPubMedCentral
54.
55.
Berridge MJ. Vitamin D and depression: cellular and regulatory mechanisms. Pharmacol Rev. 2017;69:80–92.CrossRefPubMed
56.
Tohari AM, Zhou X, Shu X. Protection against oxidative stress by vitamin D in cone cells. Cell Biochem Funct. 2016;34:82–94.CrossRefPubMed
57.
Machado CS, et al. Vitamin D3 deficiency increases DNA damage and the oxidative burst of neutrophils in a hypertensive rat model. Mutat Res Genet Toxicol Environ Mutagen. 2016;798:19–26.CrossRef
58.
Manna P, Achari AE, Jain SK. Vitamin D supplementation inhibits oxidative stress and upregulate SIRT1/AMPK/GLUT4 cascade in high glucose-treated 3T3L1 adipocytes and in adipose tissue of high fat diet-fed mice. Arch Biochem Biophys. 2017;615:22–34.CrossRefPubMed
59.
Gulley JM, Zahniser NR. Rapid regulation of dopamine transporter function by substrates, blockers and presynaptic receptor ligands. Eur J Pharmacol. 2003;479:139–52.CrossRefPubMed
60.
61.
Afonso-Oramas D, et al. The dopamine transporter is differentially regulated after dopaminergic lesion. Neurobiol Dis. 2010;40:518–30.CrossRefPubMed
62.
Chotibut DM, Apple RJ, Michael FS. Dopamine transporter loss in 6-OHDA Parkinson’s model is unmet by parallel reduction in dopamine uptake. PLoS One. 2012;7:e52322.CrossRefPubMedPubMedCentral
63.
64.
Hwang O. Role of oxidative stress in Parkinson’s disease. Exp Neurol. 2013;22:11–7.
65.
66.
Dias V, Junn E, Mouradian MM. The role of oxidative stress in Parkinson’s disease. J Parkinsons Dis. 2013;3:461–91.PubMedPubMedCentral
67.
Eyles DW, et al. Intracellular distribution of the vitamin D receptor in the brain: comparison with classic target tissues and redistribution with development. Neuroscience. 2014;268:1–9.CrossRefPubMed
68.
69.
70.
Cui X, et al. Vitamin D and the brain: genomic and non-genomic actions. Mol Cell Endocrinol. 2017;453:131–43.CrossRefPubMed
71.
Kalueff AV, Eremin KO, Tuohimaa P. Mechanisms of neuroprotective action of vitamin D(3). Biochemist. 2004;69:738–41.
72.
73.
Tansey MG, Goldberg MS. Neuroinflammation in Parkinson’s disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis. 2010;37:510–8.CrossRefPubMed
74.
Chen H, et al. Peripheral inflammatory biomarkers and risk of Parkinson’s disease. Am J Epidemiol. 2008;167:90–5.CrossRefPubMed
75.
Calvello R, et al. Vitamin D treatment attenuates neuroinflammation and dopaminergic neurodegeneration in an animal model of Parkinson’s disease, shifting M1 to M2 microglia responses. J NeuroImmune Pharmacol. 2017;12:327–39.CrossRefPubMed
76.
Mogi M, et al. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett. 1994;165:208–10.CrossRefPubMed
77.
Olanow CW, Brundin P. Parkinson’s disease and alpha synuclein: is Parkinson’s disease a prion-like disorder? Mov Disord. 2013;28:31–40.CrossRefPubMed
78.
Brabdel JP, et al. Is Parkinson’s disease a prion disease? Rev Neurol (Paris). 2015;171:812–24.CrossRef
79.
80.
81.
Stopschinski BE, Diamond MI. The prion model for progression and diversity of neurodegenerative diseases. Lancet Neurol. 2017;16:323–32.CrossRefPubMed
82.
83.
Ji LL, et al. Changes in the expression of the vitamin D receptor and LVSCC-A1C in the rat hippocampus submitted to prolonged stress. Mol Med Rep. 2004;9(4):1165–70.CrossRef
84.
Metadata
Title
Vitamin D protects dopaminergic neurons against neuroinflammation and oxidative stress in hemiparkinsonian rats
Authors
Ludmila A R Lima
Maria Janice P Lopes
Roberta O Costa
Francisco Arnaldo V Lima
Kelly Rose T Neves
Iana B F Calou
Geanne M Andrade
Glauce S B Viana
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Journal of Neuroinflammation / Issue 1/2018
Electronic ISSN: 1742-2094
DOI
https://doi.org/10.1186/s12974-018-1266-6

Other articles of this Issue 1/2018

Journal of Neuroinflammation 1/2018 Go to the issue

Research

Fas-ligand and interleukin-6 in the cerebrospinal fluid are early predictors of hypoxic-ischemic encephalopathy and long-term outcomes after birth asphyxia in term infants

Research

Splenic responses play an important role in remote ischemic preconditioning-mediated neuroprotection against stroke

Research

18F-VC701-PET and MRI in the in vivo neuroinflammation assessment of a mouse model of multiple sclerosis

Research

Epigenetic impacts of stress priming of the neuroinflammatory response to sarin surrogate in mice: a model of Gulf War illness

Research

Blockade of sustained tumor necrosis factor in a transgenic model of progressive autoimmune encephalomyelitis limits oligodendrocyte apoptosis and promotes oligodendrocyte maturation

Research

Neuroinflammation is increased in the parietal cortex of atypical Alzheimer’s disease